Department of Clinical Pharmacy, Division Laboratory and Pharmacy, University Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands.
Eur J Clin Pharmacol. 2012 Jan;68(1):83-8. doi: 10.1007/s00228-011-1084-6. Epub 2011 Jul 22.
It has been suggested that ergoline dopamine agonists can cause ischemic complications. The effect of dopamine agonists in general on the prevalence of ischemic events in patients with Parkinson's disease (PD) has not been studied.
Our aim was to investigate the association between the use of dopamine agonists and hospitalization due to ischemic events in patients with PD.
We performed a nested case-control study using the PHARMO Institute for Drug Outcome Research database. All patients issued at least one prescription for levodopa after the age of 55 years between 1994 and 2006 were initially identified. Cases were patients who were hospitalized for the first time after November 1997 for an ischemic event and were matched to as many as four controls. Exposure to dopamine agonists during the year preceding the index date was identified.
The study population consisted of 542 cases and 2,155 controls. The mean effect of dopamine agonist use 1 year prior to the index date on ischemic events requiring hospitalization is shown with 95% probability in the 0.95-1.49 range. Stratified results according to the type of dopamine agonist showed no risk differences between ergoline and nonergoline agonists.
This study does not support an association between dopamine agonist use and an increased risk of ischemic events requiring hospitalization.
已有研究表明，麦角碱类多巴胺激动剂可能导致缺血性并发症。然而，一般的多巴胺激动剂对帕金森病（PD）患者缺血性事件的发生率的影响尚未被研究。
我们旨在研究帕金森病患者使用多巴胺激动剂与缺血性事件住院之间的相关性。
我们使用 PHARMO 药物结果研究所数据库进行了一项巢式病例对照研究。所有在 1994 年至 2006 年期间年龄超过 55 岁并至少开具过一次左旋多巴处方的患者最初被确定为研究对象。病例是指在 1997 年 11 月之后首次因缺血性事件住院的患者，并与多达 4 名对照相匹配。在索引日期前一年确定使用多巴胺激动剂的情况。
该研究人群包括 542 例病例和 2155 例对照。95%概率的置信区间（CI）显示，索引日期前 1 年使用多巴胺激动剂对缺血性事件住院的平均效应在 0.95 到 1.49 范围内。根据多巴胺激动剂的类型进行分层结果显示，麦角碱和非麦角碱激动剂之间没有风险差异。
本研究不支持使用多巴胺激动剂与缺血性事件住院风险增加之间存在关联。
